Описание
Metabolic syndrome components including insulin resistance, dyslipidemia, and visceral adiposity respond differently to EPA versus DHA supplementation in clinical studies.
Figure 19
Source Paper
Do Eicosapentaenoic Acid and Docosahexaenoic Acid Have the Potential to Compete against Each Other?Cite This Figure
![Figure 19: Metabolic syndrome components including insulin resistance, dyslipidemia, and visceral adiposity respond differently to EPA versus DHA supplementation in clinical studies.]() > Source: Anandita Pal et al. "Do Eicosapentaenoic Acid and Docosahexaenoic Acid Have the Potential to Compete ." *Nutrients*, 2020. PMID: [33276463](https://pubmed.ncbi.nlm.nih.gov/33276463/)
<figure> <img src="" alt="Metabolic syndrome components including insulin resistance, dyslipidemia, and visceral adiposity respond differently to EPA versus DHA supplementation in clinical studies." /> <figcaption>Figure 19. Metabolic syndrome components including insulin resistance, dyslipidemia, and visceral adiposity respond differently to EPA versus DHA supplementation in clinical studies.<br> Source: Anandita Pal et al. "Do Eicosapentaenoic Acid and Docosahexaenoic Acid Have the Potential to Compete ." <em>Nutrients</em>, 2020. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/33276463/">33276463</a></figcaption> </figure>